2. Signaling Pathways
  3. GPCR/G Protein
  4. Prostaglandin Receptor
  5. Prostaglandin Receptor Inhibitor

Prostaglandin Receptor Inhibitor

Prostaglandin Receptor Isoform Comparison

Prostaglandin Receptor Inhibitors (87):

Cat. No. Product Name Effect Purity
  • HY-101840
    EIPA
    		Inhibitor 99.73%
    EIPA (L593754) is an orally active TRPP3 channel inhibitor with an IC50 of 10.5 μM. EIPA also enhances autophagy by inhibiting Na+/H+-exchanger 3 (NHE3). EIPA inhibits macropinocytosis as well. EIPA can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma.
  • HY-B0195
    Tranilast
    		Inhibitor 99.57%
    Tranilast (MK-341) acts as an anti-atopic agent. Tranilast suppresses production of prostaglandin D2 (PGD2, IC50= 0.1 mM). Tranilast sodium exhibits anti-inflammatory and immunomodulatory effects. Tranilast sodium antagonizes angiotensin II and inhibits its biological effects in vascular smooth muscle cells.
  • HY-N3535
    Canniprene
    		Inhibitor
    Canniprene, an isoprenylated bibenzyl unique to Cannabis sativa, is a potent inhibitor of 5-lipoxygenase (5-LO) activity (IC50=0.4 μM) and cyclooxygenase/microsomal prostaglandin E2 synthase (PGE2; IC50=10 μM). Canniprene inhibits the production of inflammatory eicosanoids and affects the generation of prostaglandins.
  • HY-108308
    Ibuprofen guaiacol ester
    		Inhibitor 98.49%
    Ibuprofen guaiacol ester (AF 2259; Metoxibutropate) is a potent and orally active prostaglandin synthesis inhibitor. Ibuprofen guaiacol ester has the potential for the research of edema and fever.
  • HY-100441
    Treprostinil
    		Inhibitor 99.98%
    Treprostinil (UT-15) is a potent DP1 and EP2 agonist with EC50 values of 0.6±0.1 and 6.2±1.2 nM, respectively.
  • HY-101840A
    EIPA hydrochloride
    		Inhibitor 98.31%
    EIPA (L593754) hydrochloride is an orally active TRPP3 channel inhibitor with an IC50 of 10.5 μM. EIPA hydrochloride also enhances autophagy by inhibiting Na+/H+-exchanger 3 (NHE3). EIPA hydrochloride inhibits macropinocytosis as well. EIPA hydrochloride can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma.
  • HY-108559
    L-161982
    		Inhibitor 99.04%
    L-161982 is a selective EP4 receptor antagonist. L-161982 completely blocks PGE2-induced ERK phosphorylation and cell proliferation of HCA-7 cells. L-161982 alleviates collagen-induced arthritis in mice.
  • HY-N0607
    Ginsenoside Ro
    		Inhibitor 99.81%
    Ginsenoside Ro (Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V) exhibits a Ca2+-antagonistic antiplatelet effect with an IC50 of 155 ?μM. Ginsenoside Ro reduces the production of TXA2 more than it reduces the activities of COX-1 and TXAS.
  • HY-N0314
    Pectolinarin
    		Inhibitor 99.89%
    Pectolinarin possesses anti-inflammatory activity. Pectolinarin inhibits secretion of IL-6 and IL-8, as well as the production of PGE2 and NO. Pectolinarin suppresses cell proliferation and inflammatory response and induces apoptosis via inactivation of the PI3K/Akt pathway.
  • HY-13448
    Nedocromil
    		Inhibitor 98.02%
    Nedocromil suppresses the action or formation of multiple mediators, including histamine, leukotriene C4 (LTC4), and prostaglandin D2 (PGD2).
  • HY-B0428
    Ozagrel
    		Inhibitor 99.74%
    Ozagrel (OKY-046)is an anti-asthmatic agent and a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC50 of 53.12 μM.
  • HY-100009
    Ufenamate
    		Inhibitor 99.89%
    Ufenamate (Flufenamic acid butyl ester) is an anthranilic acid-based anti-inflammatory drug that can be used in the study of skin diseases such as acute and chronic eczema, contact dermatitis, diaper dermatitis, miliary rashes and atopic dermatitis. Ufenamate has a certain photoprotective effect, reduces the degree of skin erythema and swelling in the photoaging model, downregulates the expression level of COX-2 and can promote the healing of mouse skull defects by secreting BMP2.
  • HY-A0221
    Ridogrel
    		Inhibitor 99.64%
    Ridogrel (R 68070) is an orally active combined thromboxane A2 synthetase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor blocker. Ridogrel is potent antiplatelet agent. Anti-inflammatory activities.
  • HY-N2252
    Licarin A
    		Inhibitor 98.48%
    Licarin A ((+)-Licarin A), a neolignan, significantly and dose-dependently reduces TNF-α production (IC50=12.6 μM) in dinitrophenyl-human serum albumin (DNP-HSA)-stimulated RBL-2H3 cells. Anti-allergic effects. Licarin A reduces TNF-α and PGD2 production, and COX-2 expression.
  • HY-B1074
    Ethamsylate
    		Inhibitor 99.49%
    Ethamsylate (Etamsylate) is an orally active anti-hemorrhagic compound. Ethamsylate inhibits biosynthesis and action of prostaglandins. Ethamsylate has the potential to maintain early hemostasis as well as restores capillary resistance. Ethamsylate acts as an antiangiogenic factor, inhibiting wound healing and matrigel tubulogenesis..
  • HY-U00027
    Quinotolast sodium
    		Inhibitor 98.38%
    Quinotolast sodium in the concentration range of 1-100 μg/mL inhibits histamine, LTC4 and PGD2 release in a concentration-dependent manner.
  • HY-P4160
    PDC31
    		Inhibitor 99.76%
    PDC31 (THG113.31; ILGHXDYK) is an allosteric and non-competitive inhibitor of FP Prostaglandin Receptor. PDC31 is the D-amino acid-based oligopeptide, is used for smooth muscle contractile agent. PDC31 decreases the strength and duration of uterine contractions in vivo, which can be used for research of preterm labor and primary dysmenorrhea (PD). PDC31 also enhances Ca2+-dependent large-conductance K+-channel in human myometrial cells.
  • HY-113756A
    Latanoprost acid
    		Inhibitor 99.62%
    Latanoprost acid, an analog of prostaglandin (PG) F2α, is an selective prostanoid receptor (FP) agonist that specifically activates the FP-PG receptor. Latanoprost acid inhibits RANKL-induced osteoclastgenesis and function by inhibiting ERK, AKT, JNK, and p38 cascade, following by the c-fos/NFATc1 pathway. Latanoprost acid is a medication which works to lower pressure inside the eyes.
  • HY-B0428A
    Ozagrel sodium
    		Inhibitor 99.98%
    Ozagrel sodium (OKY-046 sodium) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel sodium is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC50 of 53.12 μM.
  • HY-N0223
    Epibetulinic acid
    		Inhibitor ≥98.0%
    Epibetulinic acid exhibits potent inhibitory effects on NO and prostaglandin E2 (PGE2) production in mouse macrophages (RAW 264.7) stimulated with bacterial endotoxin with IC50s of 0.7 and 0.6 μM, respectively. Anti-inflammatory activity.